TITLE

Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: it ain't necessarily so

AUTHOR(S)
Wolff, Antonio C.; Abeloff, Martin D.
PUB. DATE
July 2002
SOURCE
JNCI: Journal of the National Cancer Institute;7/17/2002, Vol. 94 Issue 14, p1041
SOURCE TYPE
Academic Journal
DOC. TYPE
commentary
ABSTRACT
Examines the effectiveness of adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer among older women. Application of chemotherapy with tamoxifen; Reduction of recurrence; Effects of chemotherapy on ovaries.
ACCESSION #
7357822

 

Related Articles

  • The economic consequences of breast cancer adjuvant hormonal treatments. Pezzin, Liliana E.; O'Niel, Mallory B.; Nattinger, Ann B. // JGIM: Journal of General Internal Medicine;Nov2009 Supplement 2, Vol. 24, p446 

    Rationale: Adjuvant hormone therapy (HT) based on tamoxifen (TX) or aromatase inhibitors (AIs) has become the standard of care for treating hormone receptor -positive (HR+) breast cancer (BC) over the past 20 years. Based on clinical trial results, AI use is recommended by the...

  • Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients. Abbas, Waseem; Rao, Ranga; Rao, Ranga Raju // Indian Journal of Cancer;Oct-Nov2019, Vol. 56 Issue 4, p293 

    Adjuvant ovarian suppression, on addition to chemotherapy, reduces the risk of breast cancer in pre-menopausal women after surgery and adjuvant hormonal therapy. Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT) showed greater benefit with exemestane in high...

  • Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. V. Ziller; M. Kalder; U.-S. Albert; W. Holzhauer; M. Ziller; U. Wagner; P. Hadji // Annals of Oncology;Mar2009, Vol. 20 Issue 3, p431 

    Background: The level of adherence of various pharmacological therapies in chronic diseases varies, but is predominantly low. With tamoxifen (TAM), 23% and 50% nonadherence after 1 and 4 years have been reported. Day-to-day clinical observation suggests that adherence may even be lower with...

  • Oophorectomy in Breast Cancer-Controversies and Current Status. Singh, Gurpreet // Indian Journal of Surgery;Jun2012, Vol. 74 Issue 3, p210 

    The role of oophorectomy in the treatment of breast cancer is known for over 100 years. Ovarian ablation has a relatively large positive effect on both disease-free survival (DFS) and overall survival (OS) in premenopausal women when compared to no adjuvant treatment. Today the standard of care...

  • Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter. Fink, Michael K.; Kleeberg, Ulrich R.; Bartels, Stefan // Oncologist;2015, Vol. 20 Issue 7, following p736 

    In the subgroup of patients who suffer from metastases despite adjuvant therapy, survival after dissemination is shortened. This is partially due to an adjuvant chemotherapy‐induced resistance to previous treatment and may be similar after hormonal therapy and immunotherapy.

  • Pharmacotherapeutics of capecitabine and trastuzumab in the treatment of metastatic breast cancer. McCauley, Sarah; Carter, Gillian; Bennett, Maggie; McNally, Oonagh; Rogers, Katherine MA // British Journal of Nursing;2/13/2020, Vol. 29 Issue 3, pS4 

    Metastatic HER2-positive breast cancer is an incurable disease with a poor prognosis. This article presents a critical appraisal of two treatments commonly used in the treatment of metastatic HER2-positive breast cancer: the oral chemotherapy drug, capecitabine, and the monoclonal antibody,...

  • C linical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer. Loaiza-Bonilla, Arturo; Socola, Francisco; GlÃck, Stefan // Clinical Medicine Insights: Women's Health;2013, Issue 6, p1 

    Breast cancer is the most frequently diagnosed malignancy in women, with over 200,000 new cases diagnosed each year. Adjuvant systemic endocrine therapy has demonstrated its benefits in reducing the risk of occult micro metastatic infiltration by preventing breast cancer cells from receiving...

  • RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial. Keilty, Dana; Buchanan, Marguerite; Ntapolias, Katerina; Aleynikova, Olga; Tu, Dongsheng; Li, Xiao; Shepherd, Lois; Bramwell, Vivien; Basik, Mark // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Most women with estrogen receptor expressing breast cancers receiving anti-estrogens such as tamoxifen may not need or benefit from them. Besides the estrogen receptor, there are no predictive biomarkers to help select breast cancer patients for tamoxifen treatment. CCND1 (cyclin D1) gene...

  • Mucinous Breast Cancer with Solitary Metastasis to Humeral Head: A Case Report. Alajmi, Adil Aljarrah; Al-Hashmi, Maryam; Malik, Kamran Ahmad; Sukhpal, Sawhney; Hussein, Samir; Al-Riyami, Marwa; Al-Moundhri, Mansour // Oman Medical Journal;Sep2013, Vol. 28 Issue 5, p350 

    Breast cancer is the most common cause of metastatic deposits in the skeleton, and bone is the most common site of recurrence of breast cancer. Breast cancer metastasis most commonly affects the spine, ribs, pelvis, and proximal long bones; however, only 3.5% of breast cancer patients develop...

  • Proceedings of the 5th Kuwait International Pharmacy Conference, February 1-3, 2015. Phillips, Oludotun Adebayo; Al-Soraj, Monerah // Medical Principles & Practice;2016 Supplement, Vol. 25, p1 

    An introduction is presented which discusses various topics presented at the 2015 Kuwait International Pharmacy Conference including the role of signaling networks on treatment resistance, the changes on the treatment of breast cancer and the potential chemoprotective agents.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics